A5001295747- Colorectal Cancer Treatments and Studies
- Gastric Cancer Management and Outcomes
- Cancer Treatment and Pharmacology
- Lung Cancer Treatments and Mutations
- Genetic factors in colorectal cancer
- Cancer Genomics and Diagnostics
- Hepatocellular Carcinoma Treatment and Prognosis
- Colorectal Cancer Surgical Treatments
- Radiomics and Machine Learning in Medical Imaging
- Economic and Financial Impacts of Cancer
- Cancer Diagnosis and Treatment
- Colorectal and Anal Carcinomas
- Medical Imaging Techniques and Applications
- Cancer Immunotherapy and Biomarkers
- Neutropenia and Cancer Infections
- Pancreatic and Hepatic Oncology Research
- Melanoma and MAPK Pathways
- Colorectal Cancer Screening and Detection
- Biochemical and Molecular Research
- Cancer Mechanisms and Therapy
- Lung Cancer Research Studies
- Management of metastatic bone disease
- Bone health and treatments
- COVID-19 and healthcare impacts
- Nausea and vomiting management
Istituti di Ricovero e Cura a Carattere Scientifico
2021-2025
Instituto Nazionale Tumori Regina Elena
2021-2025
Fondazione IRCCS Istituto Nazionale dei Tumori
2021-2025
Università Campus Bio-Medico
2014-2023
Campus Bio Medico University Hospital
2015-2023
Medica (Italy)
2012-2019
Azienda Ospedaliera Universitaria Pisana
2014
<h3>Importance</h3> Based on a small retrospective study, rechallenge with cetuximab-based therapy for patients with<i>KRAS</i>wild-type metastatic colorectal cancer (mCRC) who were previously treated the same anti–epidermal growth factor receptor–based regimen might be efficacious. Recent data suggest role of liquid biopsy as tool to track molecular events in circulating tumor DNA (ctDNA). <h3>Objective</h3> To prospectively assess activity cetuximab plus irinotecan third-line treatment...
Neutrophil/lymphocyte ratio (NLR), defined as absolute neutrophils count divided by lymphocytes count, has been reported poor prognostic factor in several neoplastic diseases but only a few data are available about unresectable metastatic colorectal cancer (mCRC) patients (pts). The aim of our study was to evaluate the and predictive role NLR TRIBE trial.Pts enrolled trial were included. is multicentre phase III randomizing previously untreated mCRC pts receive FOLFOXIRI or FOLFIRI plus...
The combination of a triple-drug chemotherapy regimen with an anti-epidermal growth factor receptor (EGFR) agent as first-line treatment metastatic colorectal cancer (mCRC) showed promising activity along safety concerns in single-arm phase 2 trials. role maintenance following and anti-EGFR the optimal to be adopted are not established.To evaluate cetuximab plus modified FOLFOXIRI (mFOLFOXIRI) explore or bevacizumab RAS BRAF wild-type mCRC.In prospective, noncomparative, open-label,...
Abstract Tumour‐associated Macrophages ( TAM ) present two different polarizations: classical (M1) characterized by immunostimulation activity and tumour suppression; alternative (M2) promotion immune suppression. In this retrospective study, we evaluated the correlation between forms of with survival time in radically resected gastric cancer patients. A total 52 chemo‐ radio‐naive patients were included. Two slides prepared for each patient double‐stained CD 68/ NOS 2 or 163 five...
67 Background: Several studies show that patients (pts) with colon cancer, particularly pts right cancer (RCC), have lower survival rates than those rectal cancer. This argues colorectal should be divided into three clinical entities: RCC, left (LCC) and (RC). In refractory metastatic (mCRC), regorafenib (R) trifluridine/piracil (T) were found to improve survival. real-life subgroup analysis focused on treatment R T, sequential or not, according the above primary tumor sites. Methods:...
We know that cigarette smoking is a leading preventable cause of carcinogenesis in lung cancer. Cigarette smoke mixture more than 5000 chemical compounds, among which 60 are recognized to have specific carcinogenic potential. Carcinogens and their metabolites (i.e., N-nitrosamines polycyclic aromatic hydrocarbons) can activate multiple pathways, contributing cell transformation different ways. Nicotine, originally thought only be responsible for tobacco addiction, also involved tumor...
V600EBRAF mutated metastatic colorectal cancer (mCRC) is a subtype (10%) with overall poor prognosis, but the clinical experience suggests great heterogeneity in survival. It still unexplored real distribution of traditional and innovative biomarkers among mCRC which their role improvement prediction survival outcomes.Data tissue specimens from 155 patients treated at eight Italian Units Oncology were collected. Specimens analysed by means immunohistochemistry profiling performed on...
// Bruno Vincenzi 1 , Chiara Cremolini 2 Andrea Sartore-Bianchi 3 Antonio Russo 4 Francesco Mannavola 5 Giuseppe Perrone 6 Pantano Fotios Loupakis Daniele Rossini Elena Ongaro 7 Erica Bonazzina Emanuela Dell'Aquila Marco Imperatori Alice Zoccoli Bronte Giovanna De Maglio Gabriella Fontanini 8 Clara Natoli 9 Alfredo Falcone Santini Onetti-Muda Salvatore Siena Tonini and Aprile Department of Medical Oncology, Campus Bio-Medico University Rome, Italy Azienda Ospedaliero-Universitaria Pisana,...
Background: To assess the predictive role of lactate dehydrogenases (LDH) and fibrinogen (FBG) serum levels in metastatic colorectal cancer (mCRC) patients receiving a first-line bevacizumab-based therapy.
: Background: The optimal anti-angiogenic strategy as second-line treatment in RAS wild-type metastatic colorectal cancer (mCRC) treated with anti-EGFR (Epidermal Growth Factor Receptor) based first-line is still debated.This multicenter, real-world, retrospective study aimed at evaluating the effectiveness of Bevacizumab- and Aflibercept-based treatments after an regimen. Clinical outcomes measured were: objective response rate (ORR), progression free survival (PFS), overall (OS) adverse...
Patients with refractory mCRC rarely undergo third-line or subsequent treatment. This strategy could negatively impact their survival. In this setting, regorafenib (R) and trifluridine/tipiracil (T) are two key new treatment options statistically significant improvements in overall survival (OS), progression-free (PFS), disease control different tolerance profiles. study aimed to retrospectively evaluate the efficacy safety profiles of these agents real-world practice.